Overview

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Immunoglobulin Fc Fragments
Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin